Oak Ridge Investments LLC Sells 7,757 Shares of Insmed, Inc. $INSM

Key Points

• Oak Ridge Investments LLC sold 7,757 shares of Insmed, Inc., decreasing its position by 18.5% and leaving it with 34,188 shares valued at $3,441,000 as of the latest SEC filing.
• Insmed has received multiple **target price upgrades** from analysts, with ratings indicating strong buy enthusiasm; Stifel Nicolaus raised its target from $121 to $145, while TD Cowen increased theirs from $154 to $193.
• Insider transactions showed significant sales, with one insider selling 76,520 shares for over $11 million, reflecting a **67.73%** decrease in their ownership of the stock.

Oak Ridge Investments LLC decreased its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 18.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,188 shares of the biopharmaceutical company's stock after selling 7,757 shares during the quarter. Oak Ridge Investments LLC's holdings in Insmed were worth $3,441,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. M&T Bank Corp grew its stake in shares of Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after buying an additional 147 shares in the last quarter. ORG Partners LLC boosted its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 196 shares during the period. Cullen Frost Bankers Inc. boosted its position in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares during the period. Nisa Investment Advisors LLC boosted its position in Insmed by 6.5% during the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock worth $287,000 after purchasing an additional 228 shares during the period. Finally, Hilltop National Bank bought a new stake in Insmed during the second quarter worth approximately $28,000.

Wall Street Analysts Forecast Growth

INSM has been the subject of a number of recent analyst reports. Stifel Nicolaus upped their target price on Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. TD Cowen upped their target price on Insmed from $154.00 to $193.00 and gave the stock a "buy" rating in a research report on Thursday, October 2nd. JPMorgan Chase & Co. upped their target price on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 20th. Cowen reaffirmed a "buy" rating on shares of Insmed in a research report on Thursday, October 2nd. Finally, Evercore ISI reaffirmed an "outperform" rating and set a $180.00 target price on shares of Insmed in a research report on Wednesday, October 1st. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and a consensus target price of $149.06.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the firm's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the transaction, the insider directly owned 36,461 shares of the company's stock, valued at $5,303,252.45. This trade represents a 67.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the firm's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the transaction, the director directly owned 262,675 shares of the company's stock, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 218,820 shares of company stock valued at $28,232,955 over the last 90 days. Corporate insiders own 3.00% of the company's stock.

Insmed Stock Down 1.3%

Shares of INSM stock opened at $162.33 on Friday. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $164.58. The firm has a market cap of $34.31 billion, a PE ratio of -28.43 and a beta of 1.03. The stock has a 50 day moving average of $138.08 and a 200-day moving average of $101.99. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter last year, the firm earned ($1.94) earnings per share. The firm's quarterly revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.